KR900006010A - 소수성 상호작용 크로마토그래피에 의한 불안정한 생물학적 혼합물로부터의 처리화학약품의 제거 - Google Patents

소수성 상호작용 크로마토그래피에 의한 불안정한 생물학적 혼합물로부터의 처리화학약품의 제거 Download PDF

Info

Publication number
KR900006010A
KR900006010A KR1019890014221A KR890014221A KR900006010A KR 900006010 A KR900006010 A KR 900006010A KR 1019890014221 A KR1019890014221 A KR 1019890014221A KR 890014221 A KR890014221 A KR 890014221A KR 900006010 A KR900006010 A KR 900006010A
Authority
KR
South Korea
Prior art keywords
fat
factor
division
biological
soluble
Prior art date
Application number
KR1019890014221A
Other languages
English (en)
Other versions
KR970007941B1 (ko
Inventor
제이.보노모 리챠드
Original Assignee
원본미기재
뉴욕 블러드 센터 인코오퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22971853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900006010(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 원본미기재, 뉴욕 블러드 센터 인코오퍼레이티드 filed Critical 원본미기재
Publication of KR900006010A publication Critical patent/KR900006010A/ko
Application granted granted Critical
Publication of KR970007941B1 publication Critical patent/KR970007941B1/ko

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
    • Y10T436/255—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • External Artificial Organs (AREA)
  • Steroid Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Fats And Perfumes (AREA)

Abstract

내용 없음

Description

소수성 상호작용 크로마토그래피에 의한 불안정한 생물학적 혼합물로부터의 처리화학약품의 제거
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (19)

  1. 지용성 처리 화학약품을 함유한 생물학적 물질로부터 상기한 지용성 화학약품을 제거하는 방법에 있어서, 상기한 지용성 화학약품을 함유한 상기한 생물학적 물질을 생물학적 물질이 생물학적 활성을 가지고 있고, 생물학적 활성이 실제적으로 유지되고, 컬럼을 통과하는 동안 생물학적 물질이 흡착되지 않는, C-6 내지 C-24 수지를 함유한 소수성 상호작용 크로마토그래피 컬럼에 통과시키는 것으로 이루어지는 것을 특징으로 하는 방법.
  2. 제1항에 있어서, 수지가 활성 작용기와 지지체로 이루어지고, 활성작용기가 옥타데실 사슬로 이루어지고, 지지체가 실리카 매트릭스로 이루어지는 것을 특징으로 하는 방법.
  3. 제2항에 있어서, 실리카 매트릭스에 디메틸실란으로 차단되는 미결합 위치가 있는 것을 특징으로 하는 방법.
  4. 제1항에 있어서, 수지가 이소프로판올, 에탄올 및 아세토니트릴로 이루어지는 군으로부터 선택된 유기용매로 활성화되는 것을 특징으로 하는 방법.
  5. 제1항에 있어서, 컬럼이 125 내지 175ml/㎠/hr의 유속으로 작동되는 것을 특징으로 하는 방법.
  6. 제1항에 있어서, 그 방법이 4° 내지 37℃의 온도에서 행해지는 것을 특징으로 하는 방법.
  7. 제6항에 있어서, 온도가 20 내지 25℃인 것을 특징으로 하는 방법.
  8. 제1항에 있어서, 지용성 처리화학약품이 유기용매, 세정제, 장쇄알코올 및 할로겐화 에테르로 이루어진 군으로부터 선택되는 것을 특징으로 하는 방법.
  9. 제1항에 있어서, 지용성 처리화학약품이 림포킨 합성유도체인 것을 특징으로 하는 방법.
  10. 제1항에 있어서, 생물학적 물질이 전혈장, 혈청, 저온 침전 혈장 및 저온침전물로 이루어진 군으로부터 선택되는 것을 특징으로 하는 방법.
  11. 제1항에 있어서, 생물학적 물질이 세포인 것을 특징으로 하는 방법.
  12. 제1항에 있어서, 생물학적 물질이 혈장, 혈청, 저온침전물, 저온침전혈청, 분설 I, 분설 II, 분설 III, 분설 IV-1, 분설 IV-4, 분설 VI, 피브로넥틴, 항혈우병인자, 프레알부민, 레티놀-결합 단백질, 알부민, 알파-그로부린, 베타-그로불린, 감마-글로불린, 항트롬빈 III, 프로트롬빈, 플라스미노겐, 피브리노겐, 인자 XIII, 면역글루빈 G, 면역글루빈 A, 면역그루빈 M, 면역글루빈 D, 면역글루빈 E, 플라스민 억제인자, 프로트롬빈, 트롬빈, 항트롬빈, 인자 V, 인자 VII, 인자 VIII, 인자 IX, 인자 X, 정상세포, 암세포, 배양액에서 성장시킨 암세포의 삼출액, 배양액에서 성장시킨 정상세포의 삼출액, 하이브리도마로부터의 세포, 유전자 스플라이싱의 생성물, 식물세포 농축액, 식물세포 현탁액, 동물조직 추출물, 식물조직의 추출물 및 미생물로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 방법.
  13. 외생의 또는 내생의 지용성 화합물을 함유한 생물학적 물질로부터 상기한 지용성 화합물을 제거함으로써 생물학적 유체의 여과성 및/또는 안정성을 향상시키는 방법에 있어서, 상기한 지용성 화합물을 함유한 상기한 생물학적 물질을 생물학적 물질이 생물학적 활성을 가지고 있고, 생물학적 활성이 실제적으로 유지되고, 컬럼을 통과하는 동안 생물학적 물질이 거의 또는 전혀 흡착되지 않는, C-6 내지 C-24 수지를 함유한 소수성 상호작용 크로마토그래피 컬럼에 통과시키는 것으로 이루어지는 것을 특징으로 하는 방법.
  14. 제13항에 있어서, 수지가 활성 작용기와 지지체로 이루어지고, 활성 작용기가 옥타데실 사슬로 이루어지고 지지체가 실리칼 매트릭스로 이루어지는 것을 특징으로 하는 방법.
  15. 제14항에 있어서, 실리카 매트릭스는 디메틸실란으로 차단되는 미결합 위치가 있는 것을 특징으로 하는 방법.
  16. 제13항에 있어서, 수지가 이소프로판올, 에탄올 및 아세토니트릴로 이루어지는 군으로부터 선택한 유기용매로 활성화되는 것을 특징으로 하는 방법.
  17. 제13항에 있어서, 컬럼이 124 내지 175ml/㎠/hr 의 유속으로 작동되는 것을 특징으로 하는 방법.
  18. 제13항에 있어서, 그 방법이 4°내지 37℃ 온도에서 행해지는 것을 특징으로 하는 방법.
  19. 제18항에 있어서, 온도가 20℃ 내지 25℃인 것을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890014221A 1988-10-07 1989-10-04 소수성 상호 작용 크로마토그래피에 의한 불안정한 생물학적 혼합물로부터의 처리화학약품의 제거 KR970007941B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US256,332 1988-10-07
US07/256,332 US5094960A (en) 1988-10-07 1988-10-07 Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography

Publications (2)

Publication Number Publication Date
KR900006010A true KR900006010A (ko) 1990-05-07
KR970007941B1 KR970007941B1 (ko) 1997-05-19

Family

ID=22971853

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890014221A KR970007941B1 (ko) 1988-10-07 1989-10-04 소수성 상호 작용 크로마토그래피에 의한 불안정한 생물학적 혼합물로부터의 처리화학약품의 제거

Country Status (9)

Country Link
US (1) US5094960A (ko)
EP (1) EP0366946B1 (ko)
JP (1) JP2799747B2 (ko)
KR (1) KR970007941B1 (ko)
AT (1) ATE102071T1 (ko)
AU (1) AU621148B2 (ko)
CA (1) CA1337052C (ko)
DE (1) DE68913422T2 (ko)
ES (1) ES2051951T3 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8333446B2 (en) 2006-05-30 2012-12-18 Lg Electronics Inc. Apparatus for preventing leakage of cooling air for refrigerator

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008852A1 (de) * 1990-03-20 1991-09-26 Octapharma Ag Verfahren zur herstellung von nicht-infektioesem blutplasma
DE4125625C2 (de) * 1991-08-02 1999-12-02 Octapharma Ag Glarus Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
ATE180492T1 (de) * 1991-09-05 1999-06-15 Baxter Int Topischer fibrinogenkomplex
FR2690444B1 (fr) * 1992-04-22 1995-07-13 Rucheton Marcel Procede de preparation d'une solution d'albumine plasmatique purifiee.
AU667530B2 (en) * 1992-05-28 1996-03-28 New York Blood Center, Inc., The Removal of antibodies from blood-derived compositions while retaining coagulation factors
JPH06166634A (ja) * 1992-12-01 1994-06-14 Green Cross Corp:The プラスミノーゲン含有組成物の製造方法
DE4302163A1 (de) * 1993-01-27 1994-07-28 Thomae Gmbh Dr K Verfahren zur Reinigung von Proteinen und Peptiden
AU698154B2 (en) * 1993-06-23 1998-10-22 New York Blood Center, Inc., The System for viral inactivation of blood
US6319662B1 (en) * 1993-12-17 2001-11-20 Baxter International Inc. Method and apparatus for removing viral contaminants from a body fluid
JPH08257115A (ja) * 1995-03-20 1996-10-08 Kanegafuchi Chem Ind Co Ltd 腫瘍壊死因子の吸着剤および吸着除去方法
AU6267796A (en) * 1995-06-07 1996-12-30 Cerus Corporation Methods and devices for the removal of psoralens from blood products
US6544727B1 (en) * 1995-06-07 2003-04-08 Cerus Corporation Methods and devices for the removal of psoralens from blood products
DE19544297A1 (de) 1995-11-28 1997-06-05 Behringwerke Ag Verfahren zur Entfernung von aromatischen Verbindungen aus produkthaltigen Lösungen
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
US20020115585A1 (en) * 1996-06-07 2002-08-22 Hei Derek J. Method and devices for the removal of psoralens from blood products
US5811403A (en) 1996-09-30 1998-09-22 Vanderbilt University Polysaccharide toxin from Group B β-hemolytic Streptococcus (GBS) having improved purity
JP4630405B2 (ja) * 1997-01-06 2011-02-09 セラス コーポレーション 血液製剤から小有機化合物を減少させるための方法および装置
US20010018179A1 (en) 1998-01-06 2001-08-30 Derek J. Hei Batch devices for the reduction of compounds from biological compositions containing cells and methods of use
US20010009756A1 (en) 1998-01-06 2001-07-26 Derek Hei Flow devices for the reduction of compounds from biological compositions and methods of use
US5952235A (en) * 1997-04-14 1999-09-14 Case Western Reserve University Detection of teratogen exposure
US7611831B2 (en) * 1998-01-06 2009-11-03 Cerus Corporation Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix
ES2224415T3 (es) 1998-01-06 2005-03-01 Cerus Corporation Metodos para inhibir desactivadores patogenos en materiales biologicos.
US6495140B1 (en) 1998-01-12 2002-12-17 Her Majesty In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada Process for the isolation, recovery and purification of non-polar extractives
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
DE19834053A1 (de) * 1998-07-29 2000-03-30 Centeon Pharma Gmbh Verfahren und Mittel zur Sanatisierung von durch Viren verursachten Kontaminationen
IL136552A (en) 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
ES2285427T3 (es) * 2003-02-13 2007-11-16 Octapharma Ag Procedimiento de preparacion de una solucion de albumina.
CN1748351B (zh) 2003-09-10 2010-11-03 爱信艾达株式会社 旋转电机制造装置以及旋转电机制造方法
US6881573B2 (en) * 2003-09-12 2005-04-19 Allan L. Louderback Augmented solvent/detergent method for inactivating enveloped and non-enveloped viruses
US20060234907A1 (en) * 2004-02-13 2006-10-19 Werner Gehringer Albumin solution and process for the production thereof
DE102004009400A1 (de) 2004-02-24 2005-09-08 Zlb Behring Gmbh Fibrinogen Reinigung
AU2005265960B8 (en) * 2004-06-29 2012-01-12 Reliance Life Sciences Pvt Ltd Process for improvement of virus-safe biological fluids
GB0423196D0 (en) * 2004-10-19 2004-11-24 Nat Blood Authority Method
PL1838355T3 (pl) * 2004-10-29 2014-01-31 Cerus Corp Ulepszone sposoby wygaszania dla procesu inaktywacji czerwonych krwinek
AU2005229674B2 (en) * 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
EP1685852A1 (en) 2005-02-01 2006-08-02 Fondation pour la Recherche Diagnostique Set of disposable bags for viral inactivation of biological fluids
WO2007054297A2 (de) * 2005-11-11 2007-05-18 Csl Behring Gmbh Verwendung hydrophober interaktionschromatographie zur virusabreichung
US8480889B2 (en) * 2006-04-27 2013-07-09 Agilent Technologies, Inc. Chromatographic stationary phase
US20080293623A1 (en) * 2007-04-30 2008-11-27 Nhs Blood And Transplant Enriched haptoglobin polymers for the treatment of disease
SG10201605663UA (en) 2008-04-09 2016-09-29 Cerus Corp Improved quenching methods for red blood cell pathogen inactivation
US20120039920A1 (en) * 2009-03-31 2012-02-16 Rasmussen Jerald K Hydrophobic monomers, hydrophobically-derivatized supports, and methods of making and using the same
EP2640834B1 (en) * 2010-11-16 2017-06-28 Cadila Healthcare Limited A novel process for the purification of tissue plasminogen activator
IL210162A0 (en) 2010-12-21 2011-03-31 Omrix Biopharmaceuticals Viral inactivated platelet extract, use and preparation thereof
US20130172536A1 (en) * 2011-08-16 2013-07-04 Shenzhen Weiguang Biological Products Co.,Ltd. Intravenous Cytomegalovirus Human Immune Globulin and Manufacturing Method Thereof
CH706420A1 (fr) * 2012-04-19 2013-10-31 Valerie Soulie Procédé d'inactivation virale d'un fluide biologique, dispositif et récipient pour la mise en œuvre d'un tel procédé.
WO2014097289A1 (en) 2012-12-20 2014-06-26 Omrix Biopharmaceuticals Ltd. Viral inactivated biological mixture
KR102317930B1 (ko) 2015-02-06 2021-10-29 광저우 바이오실 바이오테크 캄파니 리미티드 트롬빈의 제조 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2750045A1 (de) * 1977-11-09 1979-05-10 Behringwerke Ag Verfahren zur entfernung von detergentien aus virusantigensuspensionen
US4464474A (en) * 1980-07-09 1984-08-07 Connaught Laboratories Limited Non-A, non-B hepatitis assay and vaccine
US4591505A (en) * 1982-04-14 1986-05-27 New York Blood Center, Inc. Process for inactivating hepatitis B virus
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4485017A (en) * 1982-12-22 1984-11-27 Cetus Corporation Isolation of human interferon by immunosorbent and high performance liquid chromatography
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4677196A (en) * 1985-09-06 1987-06-30 International Minerals & Chemical Corp. Purification and activation of proteins from insoluble inclusion bodies
US4789545A (en) * 1986-03-31 1988-12-06 New York Blood Center, Inc. Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof
US4773458A (en) * 1986-10-08 1988-09-27 William Touzani Collapsible hollow articles with improved latching and dispensing configurations
US4894330A (en) * 1986-12-23 1990-01-16 Cetus Corporation Purification of recombinant beta-interferon incorporating RP-HPLC
US4909940A (en) * 1987-12-30 1990-03-20 New York Blood Center, Inc. Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8333446B2 (en) 2006-05-30 2012-12-18 Lg Electronics Inc. Apparatus for preventing leakage of cooling air for refrigerator

Also Published As

Publication number Publication date
JP2799747B2 (ja) 1998-09-21
CA1337052C (en) 1995-09-19
DE68913422D1 (de) 1994-04-07
AU621148B2 (en) 1992-03-05
AU4155989A (en) 1990-09-13
EP0366946A1 (en) 1990-05-09
DE68913422T2 (de) 1994-06-01
US5094960A (en) 1992-03-10
ES2051951T3 (es) 1994-07-01
EP0366946B1 (en) 1994-03-02
KR970007941B1 (ko) 1997-05-19
JPH02198561A (ja) 1990-08-07
ATE102071T1 (de) 1994-03-15

Similar Documents

Publication Publication Date Title
KR900006010A (ko) 소수성 상호작용 크로마토그래피에 의한 불안정한 생물학적 혼합물로부터의 처리화학약품의 제거
Ritchie et al. Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway.
Ridge et al. Role of peroxidase when hydroxyproline-rich protein in plant cell walls is increased by ethylene
Mayadas et al. In vitro multimerization of von Willebrand factor is triggered by low pH: importance of the propolypeptide and free sulfhydryls
Stenn Epibolin: a protein of human plasma that supports epithelial cell movement.
DE68915675T3 (de) Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen.
KR890010193A (ko) 유기알코올 또는 할로겐화된 탄화수소와의 가변성 생물학적 혼합물로부터의 처리약품의 추출방법
Holley et al. Control of growth of a tumor cell by linoleic acid
Leung-Tack et al. Neutrophil chemotactic activity is modulated by human cystatin C, an inhibitor of cysteine proteases
ATE223374T1 (de) Lipidverbindungen
Sekimoto et al. Biochemical and physiological properties of a protein inducing protoplast release during conjugation in the Closterium peracerosum-strigosum-littorale complex
KR880000464A (ko) 단백질의 정제 방법
KR900003207A (ko) 트롬빈 결합성 물질 및 이의 제조방법
Saks et al. Specific inhibition of ATP-ADP translocase in cardiac mitoplasts by antibodies against mitochondrial creatine kinase
Lyttleton The antithrombin activity of heparin
JPH03501085A (ja) 化学的プロセス
ES2056108T3 (es) Empleo de interacciones anticuerpo/antigeno para proteger o modular la actividad biologica.
US5077393A (en) Method for producing vitronectin
Melsert et al. Albumin, a biologically active protein acting on Leydig cells
Malhotra Purification and characterization of dicoumarol-induced prothrombins. Barium citrate atypical (7-Gla) prothrombin
Mithieux et al. Association of purified thyroid lysosomes to reconstituted microtubules
Al Salihi et al. Purification of complement components by hydrophobic affinity chromatography on phenyl—Sepharose: Purification of human C5
Strauch et al. Biochemical analysis of actin in crane-fly gonial cells: evidence for actin in spermatocytes and spermatids--but not sperm.
Roche et al. Intersubunit cross-linking by cis-dichlorodiammineplatinum (II) stabilizes an. alpha. 2-macroglobulin" nascent" state: evidence that thiol ester bond cleavage correlates with receptor recognition site exposure
Yamagami Relationship between two kinds of hatching enzymes in the hatching liquid of the medaka, Oryzias latipes

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20111010

Year of fee payment: 15

EXPY Expiration of term